Of the 1016 bladder patients enrolled in the study, the characteristics of the study population of bladder cancer are shown in Table 1, 79 (7.8%) carried a CHEK2 mutation (all variants combined) (OR = 1.3; 95% CI 1.05–1.72; p = 0.02), including 17 (1.7%) cases with a truncating mutation (OR = 1.7; 95% CI, 1.03–2.96; p = 0.05) and 62 (6.1%) patients with the missense mutation (OR = 1.2; 95% CI, 0.95–1.64; p = 0.13). Here, CHEK2 is linked to urogenital neoplasm.